Construction and anti-tumor effects of targeted drug carriers with anti-human epidermal growth factor receptor 2 and doxorubicin

( views:304, downloads:0 )
Author:
CHEN Rong-jun(Department of Hepatobilary Surgery , The First Affiliated Hospital, Guangzhou Medical College , Guangzhou 510120, China)
HUANG Shan-shan()
WANG Xiao-ming(Department of Hepatobilary Surgery , The First Affiliated Hospital, Guangzhou Medical College , Guangzhou 510120, China)
ZHA0 Chao-chen(Department of Hepatobilary Surgery , The First Affiliated Hospital, Guangzhou Medical College , Guangzhou 510120, China)
CEN Jun-hua(Department of Hepatobilary Surgery , The First Affiliated Hospital, Guangzhou Medical College , Guangzhou 510120, China)
LI Jun(Department of Hepatobilary Surgery , The First Affiliated Hospital, Guangzhou Medical College , Guangzhou 510120, China)
Journal Title:
Chinese Journal of Biomedical Engineering
Issue:
Volume 18, Issue 03, 2012
DOI:
10.3760/cma.j.issn.1674-1927.2012.03.005
Key Word:
Drug carriers;Receptor,epidermal growth factor;Nanoparticles;Doxorubincin;Targeted

Abstract: Objective To construct targeted drug carriers with anti-human epidermal growth factor receptor 2(anti-HER2) and doxorubicin,and to determine its anti-tumor effects in vitro.Methods Doxorubicin nanoparticles (DNPs) loaded with doxorubicin were prepared by using doable emulsion method,and their appearance,distribution characteristics of diameter,Zeta potential and in vitro drug release were asscsscd.Immunonanoparticles (INPs) were then formed by using coupling agents that combined DNPs with trastuzumab (Herceptin),the human anti-HER2 antibody.The immunologic activity was determined via enzyme-linked immunosorbent assay (ELISA),and anti-tumour effects on SKBR3,the tumor cells with intense HER2 expression,via MTT method.Results The constructed nanoparticles appeared spherical or para-spherical,with a mean diameter of ( 198.2± 12.4) nm,Zeta potential of-41 mV,encapsulation ratio of 68.6% and 96-hour in vitro drug release of 50%,respectively.INPs were shown to be immunologically active to SKBR3 and SKOV3 tumor ceils,but not MCF-7,as indicated by ELISA.Additionally,comparison on SKBR3 snrvival rate suggested that INPs conferred remarkably higher tumor cell inhibitory effects than DNPs and doxorubicin (both P<0.05 ).Conclusion The immunologic activity and targeting characteristics of IN Ps may result in effective inhibition of the growth of tumor cells with highly spccialized HER2 cxpression.

  • [1]Slamon DJ,Godolphin W,Jones LA,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science,1989,244:707-712.
  • [2]Hirsch FR,Franklin WA,Veve R,et al.HER2/neu expression in malignant lung tumors.Semin Oncol,2002,29 (1 Suppl 4):51-58.
  • [3]Carter P,Presta L,Gorman CM,et al.Humanization of an antip185HER2 antibody for human cancer therapy.Proc Natl Acad Sci USA,1992,89:4285-4289.
  • [4]Speth PA,van Hoesel QG,Haanen C.Clinical pharmacokinetics ofdoxorubicin.Clin Pharmacokinet,1988,15:15-31.
  • [5]Zhang YW,Shi J,Li Y J,et al.Cardiomyocyte death in doxorubicininduced cardiotoxicity.Arch Immunol Ther Exp (Warsz),2009,57:435-445.
  • [6]Wollina U,Dummer R,Brockmeyer NH,et al.Multiccntcr study of pegylated liposomal doxorubicin in patients with cutaneous Tcell lymphoma.Cancer,2003,98:993-1001.
  • [7]Zhang Q,Yie G,Li Y,et al.Studies on the cyclosporin A loaded stearic acid nanoparticles.Int J Pharm,2000,200:153-159.
  • [8]Tewes F,Munnier E,Antoon B,et al.Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepsred by single and double emulsion methods.Eur J Pharm Biopharm,2007,66:488-492.
  • [9]Allen TM.Ligand-targeted therapeutics in anticancer therapy.Nat Rev Canccr,2002,2:750-763.
  • [10]Puri A,Loomis K,Smith B,et al.Lipid-based nanoparticles as pharmaceutical drug carriers:from concepts to clinic.Crit Rev Ther Drug Carrier Syst,2009,26:523-580.
  • [11]Dong X,Mattingly CA,Tseng MT,et al.Doxorubicin and paclitaxelloaded lipid-based nanopartieles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.Cancer Res,2009,69:3918-3926.
  • [12]Zhang Y,Li X,Zhou Y,ct al.Preparation and evaluation of poly (ethylene glycol)-poly (lactide) micelles as nanocarriers for oral delivery of cyclosporine a.Nanoscale Res Lett,2010,5:917-925.
  • [13]Koopaei MN,Dinarvand R,Amini M,et al.Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells:preparation,characterization,and cytotoxicity studies.Int J Nanomedicine,2011,6:1903-1912.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn